How important is it to start antifibrotic therapy when fibrous tissue is identified on a chest CT, and is early initiation essential?

Early Antifibrotic Therapy is Critical When Fibrous Tissue is Found on CT

If you have fibrous tissue on chest CT consistent with a progressive fibrotic interstitial lung disease (ILD), starting antifibrotic therapy promptly is essential—time matters significantly because lung function decline is often linear and irreversible, and early treatment preserves more lung capacity and may improve survival.

The Core Issue: Fibrosis is Progressive and Irreversible

The fundamental problem with pulmonary fibrosis is that decline in forced vital capacity (FVC) appears almost linear, with patients who have well-preserved lung function at baseline experiencing the same rate of decline as those with advanced disease 1. This means waiting for "significant progression" allows irreversible lung damage to accumulate. Once lung tissue becomes fibrotic, it cannot be reversed—only the rate of further decline can be slowed 1, 2.

When Antifibrotic Therapy Should Be Started

For Idiopathic Pulmonary Fibrosis (IPF)

Treatment should begin immediately upon diagnosis, regardless of disease severity 2. The "wait and watch" approach is explicitly discouraged in the literature 2. Both nintedanib and pirfenidone slow FVC decline and reduce acute respiratory deteriorations, which carry very high mortality 1.

For Progressive Pulmonary Fibrosis (PPF) - Other ILDs

The 2022 ATS/ERS/JRS/ALAT guidelines provide conditional recommendations for antifibrotic therapy in non-IPF fibrotic ILDs that demonstrate progression 3:

Nintedanib is conditionally recommended for PPF after standard management has failed 3. The guideline defines progression as meeting criteria within the past year:

• Relative decline in FVC ≥10% predicted, OR
• Relative decline in FVC 5-10% predicted PLUS worsening respiratory symptoms or increased fibrosis on CT, OR
• Worsening respiratory symptoms PLUS increased fibrosis on CT 3

Pirfenidone requires more research according to the guidelines—38% of the committee abstained from voting due to insufficient evidence, though 62% gave a conditional recommendation for its use 3.

The Time-Sensitivity Problem

Why Early Treatment Matters:

1. Linear decline: Patients lose lung function at consistent rates regardless of baseline severity 1
2. Irreversibility: Fibrotic changes cannot be reversed, only slowed 1, 2
3. Acute exacerbations: These carry extremely high mortality, and antifibrotics reduce their risk 1
4. Survival benefit: Pooled data and observational studies suggest antifibrotics improve life expectancy, though individual trials weren't powered for mortality 1

The Clinical Dilemma:

Real-world practice presents challenges 4. The strict "wait for proven progression" approach may not serve all patients optimally 4. Some considerations that warrant flexibility:

• Disease severity at baseline: More severe disease at diagnosis may warrant immediate treatment
• Specific ILD subtype: Some entities (like fibrotic hypersensitivity pneumonitis or certain connective tissue disease-related ILDs) may behave more aggressively
• Prediction of progression: If clinical features suggest high likelihood of rapid progression, earlier intervention may be justified 4

Practical Algorithm for Decision-Making

Step 1: Confirm the Diagnosis

• Is this truly fibrotic ILD on CT (honeycombing, reticulation with traction bronchiectasis involving >5% lung volume)? 5
• What is the specific ILD diagnosis? (IPF vs. other fibrotic ILD)

Step 2: For IPF - Start Treatment Immediately

• No waiting period needed 2
• Choose nintedanib or pirfenidone based on side effect profile and patient factors

Step 3: For Non-IPF Fibrotic ILD - Assess for Progression

Has the patient demonstrated progression in the past year?

• FVC decline ≥10% predicted, OR
• FVC decline 5-10% + worsening symptoms or increased CT fibrosis, OR
• Worsening symptoms + increased CT fibrosis 3

If YES: Start nintedanib (conditional recommendation) 3

If NO but high-risk features present (extensive fibrosis, UIP pattern, rapid symptom onset):

• Consider closer monitoring (3-6 month intervals)
• Discuss potential early treatment given irreversibility of decline 4
• Document baseline carefully to detect future progression quickly

Step 4: Address "Standard Management" First (for non-IPF ILD)

The guidelines note that standard management should be attempted before antifibrotics in non-IPF ILD 3. This varies by disease:

• Hypersensitivity pneumonitis: Antigen avoidance
• Connective tissue disease-ILD: Immunosuppression
• Sarcoidosis: Corticosteroids/immunosuppression

However, if standard management has failed or the disease is clearly progressive despite it, antifibrotic therapy should not be delayed 3.

Critical Pitfalls to Avoid

1. Immortal time bias in interpreting studies: Some observational studies showing mortality benefit may overestimate effects due to statistical handling of delayed treatment initiation 6. However, this doesn't negate the proven benefit on FVC decline and acute exacerbations 1.

2. Underestimating side effects: Both drugs have manageable side effects (GI symptoms with pirfenidone, diarrhea with nintedanib). Dose adjustment is effective at reducing side effects without compromising efficacy 1. Don't let fear of side effects prevent treatment.

3. Waiting for "significant" progression: By the time progression is obvious, substantial irreversible damage has occurred 1, 2.

4. Assuming stable disease will remain stable: Even patients with well-preserved lung function decline at similar rates to those with advanced disease 1.

The Bottom Line on Timing

For IPF: Start immediately upon diagnosis 2. The average life expectancy without treatment is only 3-4 years 1.

For other fibrotic ILDs: Start when progression is documented per guideline criteria 3, but maintain a low threshold and close monitoring given the irreversible nature of fibrosis 4. In clinical practice, some flexibility may be warranted for high-risk patients even before meeting strict progression criteria 4.

The evidence consistently supports that prompt treatment is critical to preserving lung function and improving outcomes 1, 2. The disease is progressive, irreversible, and fatal—delaying therapy allows preventable lung damage to accumulate.